Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Glossary Glossary
The Body Covers: The 39th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy
Session 93.I: Late-Breaker Slide Session II

September 27, 1999

Dr. Kahn reported on the phase III trial of Remmune, an HIV-1 immunogen, studied with a background of ARV therapy. The study was begun in March, 1996 and recruited 2700 patients by 5/97 at 77 sites. Patients were randomized to get Remmune or IFA (background adjuvant) in a 1:1 ratio.

Fortunately for the patients, but unfortunately for the study, HAART became available during this period. The original study was designed to look at clinical progression or death and the data safety monitoring board found that with the change in patient status brought about by HAART, the study would take far too long and require far too many patients to detect a statistically significant difference between arms. Therefore the study was terminated.

Abstract: A Randomized, Placebo-Controlled Multicenter Study of Remmune in Subjects With 300-550 CD4 Cells and Unrestricted Antiretroviral Treatments (Paper LB-21)
Authored by: J. Kahn, et al.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement